Acuta Capital Partners LLC boosted its holdings in CAS Medical Systems Inc (NASDAQ:CASM) by 0.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,263,508 shares of the medical technology company’s stock after buying an additional 46,510 shares during the quarter. CAS Medical Systems accounts for about 1.8% of Acuta Capital Partners LLC’s investment portfolio, making the stock its 13th largest position. Acuta Capital Partners LLC owned approximately 18.31% of CAS Medical Systems worth $10,264,000 as of its most recent filing with the SEC.

A number of other institutional investors have also bought and sold shares of CASM. EAM Investors LLC acquired a new position in CAS Medical Systems in the second quarter worth approximately $780,000. Renaissance Technologies LLC grew its position in CAS Medical Systems by 47.2% in the second quarter. Renaissance Technologies LLC now owns 386,539 shares of the medical technology company’s stock worth $754,000 after buying an additional 123,939 shares during the last quarter. Finally, BlackRock Inc. grew its position in CAS Medical Systems by 569.2% in the second quarter. BlackRock Inc. now owns 84,091 shares of the medical technology company’s stock worth $164,000 after buying an additional 71,525 shares during the last quarter. Hedge funds and other institutional investors own 24.81% of the company’s stock.

NASDAQ CASM opened at $2.10 on Wednesday. CAS Medical Systems Inc has a twelve month low of $0.59 and a twelve month high of $2.70. The company has a debt-to-equity ratio of -0.66, a quick ratio of 2.84 and a current ratio of 3.23. The company has a market cap of $61.82 million, a price-to-earnings ratio of -7.96 and a beta of -0.47.

CAS Medical Systems (NASDAQ:CASM) last posted its quarterly earnings data on Thursday, August 2nd. The medical technology company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The business had revenue of $5.29 million for the quarter, compared to analysts’ expectations of $5.18 million. equities analysts expect that CAS Medical Systems Inc will post -0.27 earnings per share for the current year.

Separately, ValuEngine upgraded shares of CAS Medical Systems from a “hold” rating to a “buy” rating in a research report on Thursday, May 17th.

About CAS Medical Systems

CAS Medical Systems, Inc, a medical technology company, develops, manufactures, and markets non-invasive patient monitoring products worldwide. The company provides FORE-SIGHT tissue oximeter monitors, sensors, and accessories, as well as offers FORE-SIGHT ELITE monitors. Its FORE-SIGHT absolute tissue oximeter provides non-invasive and quantitative measurement of oxygenation for cerebral tissue during surgery or critical care situations.

Recommended Story: Exchange-Traded Funds (ETFs)

Receive News & Ratings for CAS Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAS Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.